Park, Min Pyun, Jae-Chul Akter, Hafeza Binh Thanh Nguyen Kang, Min-Jung 2024-01-20T06:00:50Z 2024-01-20T06:00:50Z 2021-09-03 2015-11 0731-7085 https://pubs.kist.re.kr/handle/201004/124861 A specific peptide marker for diagnosing rheumatoid arthritis (RA) was found based on cyclic citrullinated peptide (CCP) using the following three steps: (1) analysis of the binding epitope of autoimmune antibodies using e-aminocaproic acid-modified peptides; (2) RA diagnosis using sequence-modified peptides; and (3) evaluation of the peptides' diagnostic performance for RA diagnosis. Ninety-five serum samples were analyzed by ELISA and compared using MedCalc (version 15.2.1). Microplate binding epsilon-aminocaproic acid was added to the N- or C-terminal of the CCP sequence. The N-terminal anchoring peptide assay showed 15% higher specificity compared with the C-terminal anchoring peptide assay. Based on this result, the hydrophilic C-terminal sequence of CCP was substituted with a hydrophobic amino acid. Among the sequence-modified peptides, CCP11A (in which alanine was substituted for the 11th amino acid of CCP) assay showed the highest sensitivity (87%) and specificity (100%) for RA diagnosis. Thus, CCP11A was selected as a possible specific marker peptide for RA diagnosis and further analyzed. The results of this analysis indicated that CCP11A showed better specificity than the CCP assay in both healthy individuals (11% better) and OA cohort (20% better). From these results, CCP11A was evaluated as a specific marker for diagnosing RA with higher diagnostic performance. (C) 2015 The Authors. Published by Elsevier B.V. English Elsevier BV Evaluation of a specific diagnostic marker for rheumatoid arthritis based on cyclic citrullinated peptide Article 10.1016/j.jpba.2015.06.032 1 Journal of Pharmaceutical and Biomedical Analysis, v.115, pp.107 - 113 Journal of Pharmaceutical and Biomedical Analysis 115 107 113 N scie scopus 000363439500013 2-s2.0-84938572883 Chemistry, Analytical Pharmacology & Pharmacy Chemistry Pharmacology & Pharmacy Article WORK DISABILITY ANTIBODY AUTOANTIBODIES CLASSIFICATION OSTEOARTHRITIS ASSOCIATION PERFORMANCE CRITERIA ELISA BRAF Rheumatoid arthritis Osteoarthritis CCP epsilon-aminocaproic acid Sequence modification Diagnostic marker